Awiqli is a long-acting basal insulin designed to provide steady background insulin support throughout the week.India has become one of the first countries in the world to introduce Awiqli, the world's first once-a-week basal insulin approved for clinical use, offering a new treatment option for adults living with diabetes.The launch comes at a crucial time for India, which has one of the world's highest diabetes burdens, as per a report by Reuters. More than 101 million people in the country are living with diabetes, while another 136 million are estimated to have prediabetes.Novo Nordisk said Awiqli, known generically as insulin icodec, simplifies insulin therapy by reducing the number of injections from 365 a year to just 52, while providing blood sugar control comparable to or better t